PAMIDRONATE DISODIUM
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PAMIDRONATE DISODIUM by Hikma is resorption. Approved for moderate, severe hypercalcemia associated with malignancy, with and 4 more indications. First approved in 2002.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pamidronate disodium is a bisphosphonate injection approved in 2002 for treating moderate-to-severe hypercalcemia associated with malignancy and osteolytic bone metastases in breast cancer and multiple myeloma. It works by adsorbing to bone mineral crystals and inhibiting osteoclast activity to reduce bone resorption without impairing bone formation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team focus likely shifting to market defense and transition planning rather than growth initiatives.
Mechanism of Action
resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may block dissolution of this mineral component of bone. In…
Indications (6)
Worked on PAMIDRONATE DISODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.